サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429711

製薬におけるAIの世界市場レポート 2024

AI In Pharma Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
製薬におけるAIの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

製薬におけるAIの市場規模は、今後数年間で急激に成長すると予想されています。 2028年には28.5%の年間複合成長率（CAGR）で56億2,000万米ドルに成長すると予想されます。予測期間の成長要因としては、製薬会社のクラウドベースサービスの導入、ヘルスケア支出の増加、政府のAI支援などが挙げられます。主な動向には、生成AIのイントロダクション、分子標的同定におけるAI、薬物スクリーニングの統合、AIツールの進歩、投資の増加、戦略的パートナーシップが含まれます。

製薬におけるAI市場の予想される成長は、AI開発に対する政府の支援の増加によって推進されることになります。各国政府は製薬分野におけるAIテクノロジーの変革の可能性を世界的に認識しており、支援的な政策や取り組みの導入につながっています。多くの国が、ヘルスケアおよび医薬品への応用を優先する国家AI戦略を策定しています。これらの戦略は、AIテクノロジーの開発と統合を促進し、科学の進歩を促進し、国内の現実の課題に対処するように設計されています。わかりやすい例としては、オーストラリア政府が2022年 4月に発表した、中小企業（SME）のAI調査を強化するための4,400万オーストラリアドル（2,961万米ドル）の融資プログラムがあります。この取り組みは、製薬業界を含むオーストラリアの国家優先製造部門全体でAIアプリケーションを強化することを目的とした、より広範な戦略に沿ったものです。この資金は、AI研究開発のハブとして機能し、中小企業にリソース、トレーニング、サポートを提供するデジタルケイパビリティセンターの設立に活用されます。その結果、政府支援の拡大は、予測期間における医薬品AI市場の成長の原動力となる見込みです。

製薬におけるAI市場の成長軌道は、製薬会社内でのクラウドベースのアプリケーションとサービスの採用の拡大によってさらに加速されています。クラウドベースの創薬プラットフォームは、データ分析とクラウドコンピューティングテクノロジーを活用した、製薬業界における研究開発への革新的なアプローチを表しています。これらのプラットフォームは、多様なツールと機能を提供し、プロセスにおける効率、費用対効果、コラボレーションを最適化することで、創薬手順を強化します。製薬会社は、重要な市場参入企業およびエンドユーザーとして、大量の臨床データ、化学データ、生物学データを収容できる安全なデータストレージオプションの恩恵を受けています。 2023年 3月、米国に拠点を置くテクノロジー企業であるNvidia Corporationは、ライフサイエンス調査、創薬、タンパク質工学を合理化するためにBioNeMo Cloudを導入しました。このクラウドベースのソフトウェアにより、事前トレーニングされたAIモデルへのアクセスが容易になり、独自のデータを使用したカスタマイズが可能になります。クラウドサービスとして提供されるBioNeMo Cloudは、創薬ワークフローを迅速化し、バイオテクノロジー企業アムジェンやさまざまなスタートアップ企業での採用が注目されています。製薬分野におけるクラウドベースのアプリケーションとサービスの採用の増加は、予測期間における製薬におけるAI市場の成長の主要な推進力になると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の製薬におけるAI市場、テクノロジー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • コンテキスト認識型処理
  • 自然言語処理
  • クエリメソッド
  • ディープラーニング
  • 世界の製薬におけるAI市場、医薬品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 低分子
  • 高分子
  • 世界の製薬におけるAI市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 診断
  • 臨床試験調査
  • 創薬
  • 研究開発
  • 伝染予測

第7章 地域および国の分析

  • 世界の製薬におけるAI市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の製薬におけるAI市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 市場の競合情勢
  • 市場企業プロファイル
    • Concerto HealthAI
    • Alphabet Inc.
    • OWKIN
    • Nvidia Corporation
    • PathAI

第31章 その他の大手および革新的な企業

  • Insilico Medicine
  • Exscientia
  • Microsoft Corporation
  • XtalPi
  • Intel
  • Standigm
  • Takeda Pharmaceutical Company Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • China National Pharmaceutical Group Co. Ltd.（Sinopharm）
  • Jiangsu Hengrui Medicine Co. Ltd
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharma
  • Alliance Pharm Pte Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14682

AI in pharmaceuticals involves the application of automated algorithms to perform tasks typically requiring human intelligence. Within this realm, AI solutions effectively analyze extensive datasets, including disease patterns, and aid in determining optimal medication formulations for treating specific ailments.

The market analysis of artificial intelligence (AI) in the pharmaceutical sector, as detailed in the report, is segmented based on technology, encompassing context-aware processing, natural language processing, querying methods, and deep learning. Additionally, it is categorized by drug type, covering small molecules and large molecules. Furthermore, the segmentation includes various applications such as diagnosis, clinical trial research, drug discovery, research and development, and epidemic prediction.

The artificial intelligence (AI) in pharma market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in pharma market statistics, including artificial intelligence (AI) in pharma industry global market size, regional shares, competitors with artificial intelligence (AI) in pharma market share, detailed artificial intelligence (AI) in pharma market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in pharma industry. This artificial intelligence (AI) in pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ai in pharma market size has grown exponentially in recent years. It will grow from $1.58 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 30.4%. The growth observed during the historic period can be attributed to two key factors such as the increased adoption of artificial intelligence (AI) for cost-efficient drug discovery and the rising implementation of AI in radiology.

The ai in pharma market size is expected to see exponential growth in the next few years. It will grow to $5.62 billion in 2028 at a compound annual growth rate (CAGR) of 28.5%. Forecast period growth drivers include pharma firms adopting cloud-based services, increased healthcare spending, government backing AI. Key trends involve Introduction of generative AI, AI in molecular target identification, drug screening integration, AI tool advancements, increased investments, strategic partnerships.

The anticipated growth of the AI in pharma market is set to be propelled by the increasing government support for AI development. Governments globally acknowledge the transformative potential of AI technologies within the pharmaceutical sector, leading to the implementation of supportive policies and initiatives. Numerous countries have formulated national AI strategies that prioritize healthcare and pharmaceutical applications. These strategies are designed to catalyze the development and integration of AI technology, fostering scientific advancements and addressing real challenges within the country. An illustrative example is the Australian government's announcement in April 2022 of a financing program amounting to AUD44 million ($29.61 million) to bolster AI research among small and medium-sized enterprises (SMEs). This initiative aligns with a broader strategy aimed at enhancing AI applications across Australia's national manufacturing priority sectors, including the pharmaceutical industry. The funds will be utilized to establish digital capability centers, serving as hubs for AI research and development, offering resources, training, and support to SMEs. Consequently, the growing government support is poised to be a driving force behind the growth of the AI in pharma market in the forecast period.

The growth trajectory of the AI in pharma market is further fueled by the escalating adoption of cloud-based applications and services within pharmaceutical companies. Cloud-based drug discovery platforms represent an innovative approach to research and development in the pharmaceutical industry, leveraging data analytics and cloud computing technologies. These platforms enhance drug discovery procedures by providing a diverse array of tools and functionalities, optimizing efficiency, cost-effectiveness, and collaboration in the process. Pharmaceutical companies, as significant market participants and end-users, benefit from secure data storage options that accommodate large volumes of clinical, chemical, and biological data. In March 2023, Nvidia Corporation, a US-based technology company, introduced BioNeMo Cloud to streamline life sciences research, drug discovery, and protein engineering. This cloud-based software facilitates access to pre-trained AI models, allowing customization with proprietary data. BioNeMo Cloud, offered as a cloud service, expedites drug discovery workflows, with notable adoption by biotech company Amgen and various startups. The increasing adoption of cloud-based applications and services within the pharmaceutical sector is expected to be a key driver for the growth of the AI in pharma market in the forecast period.

An important trend in the AI for the pharma market is the introduction of new AI tools by companies, aiming to provide significant benefits to pharmaceutical companies. AI technology contributes to various aspects of the pharmaceutical industry, including quality control, predictive maintenance, waste reduction, design optimization, and process automation. In August 2022, Sanford Health and Sharp HealthCare, both US-based non-profit healthcare organizations, collaborated with Dandelion Health, a US-based healthcare AI company, to unveil a comprehensive data platform. Named the Dandelion Platform, this initiative provides health institutions with access to high-quality and representative patient data for the development of clinical AI tools. The platform enables health AI developers to securely access patient datasets, encompassing images, waveforms, and structured health records. This accessibility facilitates the creation of tools and products that can benefit both patients and clinicians.

Companies operating in the AI for pharma market are increasingly directing their focus towards the application of generative AI in improving medical consultations. Generative AI, a subfield of artificial intelligence dedicated to creating new data instances resembling existing data, has found its way into the pharmaceutical industry, offering the potential to revolutionize drug discovery, development, and medical records management. In October 2023, Ubie, a Japan-based medical AI startup, introduced a novel Generative AI feature designed for doctors. This feature, known as the 'Medical Interview Summary Function,' utilizes a Large Language Model (LLM) to generate AI-based summaries from patient visits. Specifically, it summarizes the 20-30 questions related to symptoms and lifestyle habits that patients answer on the 'Ubie Medical Navi' product. The LLM then presents this summary on the doctor's PC screen, enabling quick comprehension of the patient's symptoms and concerns. This innovation serves to enhance the quality of medical consultations by providing efficient and comprehensive summaries for healthcare professionals.

In October 2021, Nurosene Health Inc., a Canadian company specializing in AI-driven technology for mental performance and wellness, acquired Netramark Incorporated for an undisclosed sum. This acquisition is intended to bolster Nurosene Health's AI-based neuroscience product portfolio. Netramark Incorporated, also based in Canada, focuses on pharmaceutical technology, employing AI, advanced mathematical techniques, and quantum computing to enhance new drug development, clinical trials, and diagnoses.

Major companies operating in the ai in pharma market report are Concerto HealthAI, Alphabet Inc., OWKIN, Nvidia Corporation, PathAI, Insilico Medicine, Exscientia, Microsoft Corporation, XtalPi, Intel, Standigm, Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Jiangsu Hengrui Medicine Co. Ltd, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharma, Alliance Pharm Pte Ltd., Shanghai Pharmaceuticals, DeepMind, GlaxoSmithKline, Sanofi, Bayer, Renalytix AI, Merck, AstraZeneca, Iktos, Benevolent AI, Novartis, Ardigen, Botkin, Webiomed, Care Mentor AI, Diagnocat, IBM Corporation, Atomwise Inc., Cloud Pharmaceuticals, Bioage, NuMedii, Envisagenics, Aria Pharmaceuticals, Verge Genomics, Berg LLC, Cyclica, IQVIA, Roche, Pfizer, PRA Health Science, Gesto, Intensicare, Epitrack, Deep Genomics Inc., Welltok Inc., Oncora Medical, Recursion Pharmaceuticals Inc., Nucleai, Pepticom, Rology, hearX Group, DilenyTech, iNNOHEALTH Technology Solutions

North America was the largest region in the AI in pharma market in 2023. The regions covered in the ai in pharma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ai in pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The AI in pharma market includes revenues earned by entities by implementing quality control, addressing supply chain problems in the production line, and minimizing material waste. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

AI In Pharma Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ai in pharma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ai in pharma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ai in pharma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Technology: Context-Aware Processing; Natural Language Processing; Querying Method; Deep Learning
  • 2) By Drug Type: Small Molecule; Large Molecules
  • 3) By Application: Diagnosis; Clinical Trial Research; Drug Discovery; Research and Development; Epidemic Prediction
  • Companies Mentioned: Concerto HealthAI; Alphabet Inc.; OWKIN; Nvidia Corporation; PathAI
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. AI In Pharma Market Characteristics

3. AI In Pharma Market Trends And Strategies

4. AI In Pharma Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global AI In Pharma Market Size and Growth

  • 5.1. Global AI In Pharma Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global AI In Pharma Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global AI In Pharma Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. AI In Pharma Market Segmentation

  • 6.1. Global AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Context-Aware Processing
  • Natural Language Processing
  • Querying Method
  • Deep Learning
  • 6.2. Global AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Small Molecule
  • Large Molecules
  • 6.3. Global AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnosis
  • Clinical Trial Research
  • Drug Discovery
  • Research and Development
  • Epidemic Prediction

7. AI In Pharma Market Regional And Country Analysis

  • 7.1. Global AI In Pharma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global AI In Pharma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific AI In Pharma Market

  • 8.1. Asia-Pacific AI In Pharma Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China AI In Pharma Market

  • 9.1. China AI In Pharma Market Overview
  • 9.2. China AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India AI In Pharma Market

  • 10.1. India AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan AI In Pharma Market

  • 11.1. Japan AI In Pharma Market Overview
  • 11.2. Japan AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia AI In Pharma Market

  • 12.1. Australia AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia AI In Pharma Market

  • 13.1. Indonesia AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea AI In Pharma Market

  • 14.1. South Korea AI In Pharma Market Overview
  • 14.2. South Korea AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe AI In Pharma Market

  • 15.1. Western Europe AI In Pharma Market Overview
  • 15.2. Western Europe AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK AI In Pharma Market

  • 16.1. UK AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany AI In Pharma Market

  • 17.1. Germany AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France AI In Pharma Market

  • 18.1. France AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy AI In Pharma Market

  • 19.1. Italy AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain AI In Pharma Market

  • 20.1. Spain AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe AI In Pharma Market

  • 21.1. Eastern Europe AI In Pharma Market Overview
  • 21.2. Eastern Europe AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia AI In Pharma Market

  • 22.1. Russia AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America AI In Pharma Market

  • 23.1. North America AI In Pharma Market Overview
  • 23.2. North America AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA AI In Pharma Market

  • 24.1. USA AI In Pharma Market Overview
  • 24.2. USA AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada AI In Pharma Market

  • 25.1. Canada AI In Pharma Market Overview
  • 25.2. Canada AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America AI In Pharma Market

  • 26.1. South America AI In Pharma Market Overview
  • 26.2. South America AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil AI In Pharma Market

  • 27.1. Brazil AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East AI In Pharma Market

  • 28.1. Middle East AI In Pharma Market Overview
  • 28.2. Middle East AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa AI In Pharma Market

  • 29.1. Africa AI In Pharma Market Overview
  • 29.2. Africa AI In Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa AI In Pharma Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa AI In Pharma Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. AI In Pharma Market Competitive Landscape And Company Profiles

  • 30.1. AI In Pharma Market Competitive Landscape
  • 30.2. AI In Pharma Market Company Profiles
    • 30.2.1. Concerto HealthAI
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Alphabet Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. OWKIN
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Nvidia Corporation
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. PathAI
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. AI In Pharma Market Other Major And Innovative Companies

  • 31.1. Insilico Medicine
  • 31.2. Exscientia
  • 31.3. Microsoft Corporation
  • 31.4. XtalPi
  • 31.5. Intel
  • 31.6. Standigm
  • 31.7. Takeda Pharmaceutical Company Ltd.
  • 31.8. Otsuka Pharmaceutical Co. Ltd.
  • 31.9. China National Pharmaceutical Group Co. Ltd. (Sinopharm)
  • 31.10. Jiangsu Hengrui Medicine Co. Ltd
  • 31.11. Cipla Limited
  • 31.12. Aurobindo Pharma Limited
  • 31.13. Dr. Reddy's Laboratories Ltd.
  • 31.14. Sun Pharma
  • 31.15. Alliance Pharm Pte Ltd.

32. Global AI In Pharma Market Competitive Benchmarking

33. Global AI In Pharma Market Competitive Dashboard

34. Key Mergers And Acquisitions In The AI In Pharma Market

35. AI In Pharma Market Future Outlook and Potential Analysis

  • 35.1 AI In Pharma Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 AI In Pharma Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 AI In Pharma Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer